MedinCell Announces the Initiation of Coverage of Its Stock by Portzamparc - BNP Paribas Group
27 Março 2023 - 1:21PM
Business Wire
Regulatory News:
MedinCell (Paris:MEDCL):
- Entitled "Liberating blockbusters over the long term", the
Portzamparc - BNP Paribas Group report recommends the stock as a
buy with a target price of €14.4 per share.
- This new coverage comes as the first product based on
MedinCell's long-acting injectable technology is expected to be
commercialized in the U.S. in the first half of 2023 (subject to
FDA approval); two other products are in Phase 3, with several
others in development.
- MedinCell was recently awarded "Prime" status by ISS ESG for
its sustainability performance, placing it in the top 10% of
companies in the pharmaceutical and biotech industry.
- MedinCell is also covered by Bryan Garnier, Kepler
Cheuvreux, ODDO-BHF and TP ICAP.
About MedinCell
MedinCell is a pharmaceutical technology company that is
developing a portfolio of long-acting injectable products in
various therapeutic areas by combining its proprietary BEPO®
technology with active ingredients already known and marketed. U.S.
FDA approval for the first product using BEPO® technology for
patients with schizophrenia is expected in H1 2023. Two other
products are in clinical Phase 3. In addition, several programs
should enter the clinic in 2023 and 2024, including two Global
Health initiatives in women’s health (contraception) and malaria,
supported by the Bill & Melinda Gates Foundation and Unitaid
respectively. Through the controlled and extended release of the
active pharmaceutical ingredient, MedinCell makes medical
treatments more efficient, particularly thanks to improved
compliance, and to a reduction in the quantity of medication
required. The BEPO® technology makes it possible to control and
guarantee the regular delivery of a drug at the optimal therapeutic
dose for several days, weeks or months, depending on the product,
starting from the subcutaneous or local injection of a simple
deposit of a few millimeters, fully bioresorbable. BEPO®
biocompatible polymers, the key components of each MedinCell
formulation, are produced and scaled-up at GMP quality level, and
already producible at commercial stage through MedinCell’s
joint-venture with Corbion (Euronext - CRBN). MedinCell
collaborates with tier one pharmaceuticals companies and
foundations to improve Global Health through innovative therapeutic
options. Based in Montpellier, MedinCell is a public company
(Euronext, MEDCL), currently employing 155 people from over 30
different nationalities. www.medincell.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230327005576/en/
MedinCell David Heuzé Head of Communications
david.heuze@medincell.com +33 (0)6 83 25 21 86
NewCap Louis-Victor Delouvrier / Alban Dufumier
Relations investisseurs medincell@newcap.eu +33 (0)1 44 71
94 94
NewCap Nicolas Merigeau Relations médias
medincell@newcap.eu +33 (0)1 44 71 94 94
Medincell (EU:MEDCL)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Medincell (EU:MEDCL)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024